BIOMAT Database Logo BIOMAT Database Logo

Zidovudine-resistant variants of HIV-1 in lung. 1997

A Gates, and R Coker, and R Miller, and D Mitchell, and J Williamson, and J Clarke

UI MeSH Term Description Entries
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

A Gates, and R Coker, and R Miller, and D Mitchell, and J Williamson, and J Clarke
Zidovudine-resistant variants of HIV-1 in brain.
October 1993, Lancet (London, England),
A Gates, and R Coker, and R Miller, and D Mitchell, and J Williamson, and J Clarke
Detection of zidovudine-resistant variants of HIV-1 in genital fluids.
March 1993, AIDS (London, England),
A Gates, and R Coker, and R Miller, and D Mitchell, and J Williamson, and J Clarke
Transmission of zidovudine-resistant HIV-1.
December 1993, AIDS (London, England),
A Gates, and R Coker, and R Miller, and D Mitchell, and J Williamson, and J Clarke
Characterization of zidovudine resistant variants of HIV-1 isolated from patients on prolonged therapy.
January 1992, Drugs under experimental and clinical research,
A Gates, and R Coker, and R Miller, and D Mitchell, and J Williamson, and J Clarke
Zidovudine resistant HIV.
April 1989, BMJ (Clinical research ed.),
A Gates, and R Coker, and R Miller, and D Mitchell, and J Williamson, and J Clarke
Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. Canadian Zidovudine Multi-Centre Study Group.
July 1989, AIDS (London, England),
A Gates, and R Coker, and R Miller, and D Mitchell, and J Williamson, and J Clarke
Mother to child transmission of zidovudine-resistant HIV-1.
January 1994, Lancet (London, England),
A Gates, and R Coker, and R Miller, and D Mitchell, and J Williamson, and J Clarke
Transmission of zidovudine-resistant HIV-1 through heterosexual contacts.
July 1994, AIDS (London, England),
A Gates, and R Coker, and R Miller, and D Mitchell, and J Williamson, and J Clarke
[The sexual transmission of zidovudine-resistant HIV-1 strains].
October 1995, Medicina clinica,
A Gates, and R Coker, and R Miller, and D Mitchell, and J Williamson, and J Clarke
Prevalence of zidovudine-resistant HIV-1 among rapid progressors.
September 1996, AIDS (London, England),
Copied contents to your clipboard!